A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds

Completed · Not applicable

Conditions studied: Moderate to Severe Nasolabial Folds

In brief

A prospective, multicenter, within-subject controlled study of the safety and effectiveness of JUVÉDERM VOLIFT® XC versus Control for the correction of moderate to severe nasolabial folds (NLFs).

Key facts

Study ID

NCT01976663

Run by

Allergan

People needed

126

Starts

2013-10-29

Expected to finish

2015-10-26

Last updated by the study team

2019-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 2 visible moderate to severe nasolabial folds
• Agree to refrain from undergoing other anti-wrinkle/volumizing treatments in the lower two-thirds of the face for the duration of the study

You may not qualify if…

• Undergone facial tissue augmentation with dermal fillers in the lower two-thirds of the face within the past 12 months
• Undergone facial tissue augmentation with fat injections, botulinum toxin injections in the lower two-thirds of the face, mesotherapy, or cosmetic facial procedures in the face or neck within the past 6 months
• Received semi-permanent fillers or permanent facial implants anywhere in the lower face

Where it is running

• Total Skin and Beauty Dermatology Center P.C. — Birmingham, Alabama, United States
• Vitiligo and Pigmentation Institute of Southern California — Los Angeles, California, United States
• Study site — San Francisco, California, United States
• Dermatology Research Institute, LLC — Coral Gables, Florida, United States
• Skin Research Institute — Coral Gables, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.